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A Meta-Analysis of Randomized Controlled Trials
Laurent Fauchier, MD, PHD, Bertrand Pierre, MD, Axel de Labriolle, MD, Caroline Grimard, MD,
Noura Zannad, MD, Dominique Babuty, MD, PHD
Tours, France
Objectives To improve the evaluation of the possible antiarrhythmic effect of statins, we performed a meta-analysis of ran-
domized trials with statins on the end point of incidence or recurrence of atrial fibrillation (AF).
Background The use of statins had been suggested to protect against AF in some clinical observational and experimental
studies but has remained inadequately explored.
Methods A systematic review of controlled trials with statins was performed. Eligible studies had to have been ran-
domized controlled parallel-design human trials with use of statins that collected data on incidence or re-
currence of AF.
Results Six studies with 3,557 patients in sinus rhythm were included in the analysis. Three studies investigated the use
of statins in patients with a history of paroxysmal AF (n  1) or persistent AF undergoing electrical cardioversion
(n  2), and 3 investigated the use of statins in primary prevention of AF in patients undergoing cardiac surgery
or after acute coronary syndrome. Incidence or recurrence of AF occurred in 386 patients. Overall, the use of
statins was significantly associated with a decreased risk of AF compared with control (odds ratio [OR] 0.39,
95% confidence interval [CI] 0.18 to 0.85, p  0.02). Benefit of statin therapy seemed more marked in second-
ary prevention of AF (OR 0.33, 95% CI 0.10 to 1.03, p  0.06) than for new-onset or postoperative AF (OR 0.60,
95% CI 0.27 to 1.37, p  0.23).
Conclusions Use of statins was significantly associated with a decreased risk of incidence or recurrence of AF in patients in
sinus rhythm with a history of previous AF or undergoing cardiac surgery or after acute coronary
syndrome. (J Am Coll Cardiol 2008;51:828–35) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.063i
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ahe 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
oA) reductase inhibitors (statins) are hypothesized to have
benefit against arrhythmias in addition to well-established
econdary prevention benefits for atherosclerotic coronary
rtery disease, yet the data are inconsistent. The use of
tatins had been suggested to protect against atrial fibrilla-
ion (AF) in some clinical and experimental studies but
emained inadequately explored. Specifically, observational
tudies provided evidence supporting a protective role of
tatins against AF. However, insufficient data are available
t this time to allow recommendations for prevention of AF
ith statins (1,2). To improve the evaluation of the possible
enefit of statins, we performed a meta-analysis of random-f
rom Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France.
Manuscript received August 17, 2007; accepted September 19, 2007.zed trials with statins on the end point of incidence or
ecurrence of AF.
ethods
ata collection. We searched through Medline for all
andomized controlled trials published from January 1980
hrough June 2007 that compared statins with placebo or a
ontrol treatment. We conducted text searches with the
erms “statin,” “atrial fibrillation,” and “random.” We looked
or randomized controlled outcome trials that met all of the
ollowing specified criteria: 1) direct comparison between a
tatin and control treatment or placebo regardless of the
ackground therapy in either group; 2) publication before
une 1, 2007 in peer-reviewed journals indexed in Medline;
) incidence or recurrence of AF as a specified event,
lthough not necessarily a primary end point; and 4)
ollow-up of at least 3 weeks. We also manually searched
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February 26, 2008:828–35 Statins and Atrial Fibrillationeferences from selected clinical trials, recent meta-analyses,
nd review articles. Finally, we reviewed abstracts from the
001 to 2007 conference proceedings of the American
ollege of Cardiology, American Heart Association, and
uropean Society of Cardiology. The final search identified
trials (3–8) that fulfilled all inclusion criteria. We ex-
racted information on study design, sample characteristics,
ample size, intervention strategies, outcome measures, and
ther study characteristics from the included randomized
ontrolled trials and/or previously published data for results
ublished in abstract form (4,9,10). We reviewed the
ethodologic quality of randomized controlled trials by
sing a scoring system developed by Jadad et al. (11). The
umber of events in each trial were extracted when available
n the basis of an intention-to-treat approach. All the
nalysis on the end point of AF was performed at the trial
evel, and none of the data of the individual studies were
btained from sponsoring institutions. A Quality of Report-
ng of Meta-Analysis (QUOROM) (12) flow diagram of
he study selection process is illustrated in Figure 1.
tatistical analysis. We calculated values for agreement
sing the methods described by Fleiss (13). We calculated
n odds ratio (OR) for each study outcome to allow for
ooling of similar outcomes. We calculated ORs and 95%
onfidence intervals (CIs) for incidence or recurrence of AF
f each trial separately and for combinations of studies
ccording to fixed-effect and random-effect models. We
sed a chi-square test to assess heterogeneity. In the
resence of statistical homogeneity, defined as a chi-square
est p value more than 0.10, we analyzed the data using
xed-effects models. Pooled ORs and 95% CIs for fixed-
ffects models were calculated on the basis of the Mantel-
aenszel method (14). Otherwise, we used random-effects
odels (15). The p value threshold for statistical signifi-
ance was set at 0.05 for effect sizes. We also generated a
unnel plot of randomized, controlled trials with estimable
Rs for considered end point to assess the presence of
ublication bias. We plotted the inverse of the standard
rror of the natural logarithm of the OR against the OR.
tatistical calculations were performed by using RevMan,
ersion 4.2.6 (The Cochrane Collaboration, Oxford, United
ingdom). No funding source had a role in the design of the
tudy or in the decision to submit the manuscript for
ublication.
esults
ix studies with 3,557 patients in sinus rhythm were
ncluded in the analysis. Three studies investigated the use
f statins in patients with a history of paroxysmal AF (n 
) or persistent AF undergoing electrical cardioversion (n
), and 3 investigated the use of statins in primary preven-
ion of AF in patients undergoing cardiac surgery (post-
perative AF, n  2) or after acute coronary syndrome
new-onset AF, n  1). Table 1 summarizes the character-
stics of the 6 trials. All included controlled trials wereandomized and received Jadad
cores of 2 (n  2), 3 (n  1), 4
n  1), or 5 (n  2) points. The
eligible trials included 1,542
atients randomized to statins
nd 1,559 patients randomized
o placebo or control regimen.
he following statins were stud-
ed: atorvastatin (n  5), and
ravastatin (n  1). Intervention
oses for statins were variable. Comparisons were made
ith placebo (n  4) or a control regimen (n  2). In this
atter situation, medication and antiarrhythmic use was
imilar in the control group and in the statin group,
articularly for the use of beta-blocker drugs (25% in the
tudy by Ozaydin et al. [6] and 65% in the study by Tveit et
l. [3]).
Follow-up durations varied from 3 to 26 weeks. All 6
tudies reported AF outcomes. For the considered end
oint, Funnel plot of trials with estimable ORs appeared to
e relatively symmetrical, suggesting the absence of major
ublication bias (Fig. 2). Coronary artery disease was
resent in 3,306 of 3,557 patients (93%). Coronary artery
Figure 1 Selection Process for Randomized
Controlled Trials on Statin and AF
AF  atrial fibrillation.
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
CRP  C-reactive protein
LDL  low-density
lipoprotein
OR  odds ratio
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Statins and Atrial Fibrillation February 26, 2008:828–35isease was present in 219 of 470 of the patients (47%)
hen the MIRACL (Myocardial Ischemia Reduction with
ggressive Cholesterol Lowering) study published in ab-
tract form was removed. Other characteristics of patients in
ach study, including concomitant medical treatment, are in
ables 2 and 3. Incidence or recurrence of AF occurred in
86 patients: 165 of 1,775 in patients treated with statin
ersus 221 of 1,782 in control subjects. Data of the
omparison groups for end point were not homogeneous on
he basis of the chi-square statistic. Therefore, we assumed
andom-effects models. Overall, the use of statins was
ignificantly associated with a decreased risk of recurrence of
F compared with control (OR 0.39, 95% CI 0.18 to 0.85,
 0.02) (Fig. 3). The benefit of statin therapy seemed
ore marked in secondary prevention of AF (OR 0.33, 95%
I 0.10 to 1.03, p  0.06) than for new-onset or postop-
rative AF (OR 0.60, 95% CI 0.27 to 1.37, p  0.23) (Fig.
). When atorvastatin was considered alone, benefit was
igher (OR 0.30, 95% CI 0.12 to 0.78, p 0.01 on the end
oint of both incidence or recurrence of AF) (Fig. 4).
inally, results were similar when ORs were calculated after
xclusion of the MIRACL study, which was only published
n abstract form (OR 0.30, 95% CI 0.11 to 0.76, p  0.01,
n the end point of either incidence or recurrence of AF) or
hen studies with Jadad score 3 were removed from the
nalysis (OR 0.34, 95% CI 0.12 to 0.96, p  0.04) (Fig. 5).
iscussion
ur systematic analysis suggests that use of statins was
ignificantly associated with a decreased risk of incidence or
ecurrence of AF in patients in sinus rhythm with a history
f previous AF or undergoing cardiac surgery or after acute
oronary syndrome. This beneficial effect seemed more
Figure 2 Funnel Plot of the Meta-Analysis
Review: statins versus placebo or control regimen for the end point of first epi-
sode (new-onset or post-operative) or recurrence of atrial fibrillation (AF). Fun-
nel plot allows assessment of publication bias. Bias is suspected if the plots
are asymmetric on each side of the dashed line. Present plot shows no clear
evidence of bias. OR  odds ratio.Tr
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February 26, 2008:828–35 Statins and Atrial Fibrillationarked in the prevention of AF recurrences than in primary
revention of AF, although this might not be certain,
ecause none of the subset analyses came out statistically
ignificant. The lower number of patients with new-onset or
ost-operative AF might in part explain the lack of signif-
cance for this subgroup. Of note, although the number of
atients in each study was highly variable, we had a
elatively well balanced contribution of each of the 6 studies
ith weight ranging from 10% to 22%.
Duration of follow-up in the 6 studies was variable and
ight seem relatively short. However, different types of AF
ave varying expected times to development or onset. In each
tudy, patients were appropriately monitored on the basis of
he type of AF. Recurrences of paroxysmal AF or AF after
ardioversion frequently occur within the first month (1). All of
he patients with recurrent AF included in our analysis had a
ollow-up period 1 month (6 weeks to 6 months). Postop-
rative AF patients were followed for at least 3 days and up to
0 days. Because the risk of developing postoperative AF is
reatest on postoperative days 2 and 3 and lower after day 10,
hese periods of follow-up were sufficient (16). The MIRACL
tudy was the only one that did not show a clear reduction in
F with atorvastatin use, particularly in the subgroup of
atients that had new-onset AF analyzed with a relatively short
ollow-up of 16 weeks. This shorter duration of follow-up
considering new-onset AF) might explain why a beneficial
ffect against AF was not observed with statin in the MIR-
CL study. This relatively inadequate follow-up duration
ight also explain the lack of benefit of statin use on the
rimary prevention of AF (postoperative or new-onset AF),
ecause these results were essentially driven by the MIRACL
tudy.
The present analysis ignored in part varying doses of
tatins and varying durations of therapy, as in most of
eta-analyses. Because populations were different, we
hought it was inappropriate to compare the OR in each
rial and draw precise conclusions on dose effect. However,
he benefit against AF did not seem clearly related to statin
ose, particularly for atorvastatin use, because OR was not
ower in the ARMYDA-3 (Atorvastatin for Reduction of
Yocardial Dysrhythmia After cardiac surgery) study and
he MIRACL studies in which a high dose of atorvastatin
as used (40 and 80 mg/day, respectively). A beneficial
ffect was not found in the only study performed with
ravastatin in contrast to those that used atorvastatin.
hether the benefit obtained against AF, at least at some
xtent, in almost all the populations studied with atorvasta-
in might be obtained with other statins is unknown.
The mechanisms by which statins might prevent AF have
een in part delineated. Inflammation is involved in the
evelopment, recurrence, and persistence of AF (17). These
onditions are associated with enhanced myocardial tissue
nflammation and atrial remodeling that might serve as a
ubstrate for the development of AF (2). Moreover, elevated
C-reactive protein (CRP) levels have been shown to beBa T T M C O A D AA

i
d
s
w
b
a
C
a
f
b
k
a
a
B6
*
abbrevi
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Statins and Atrial Fibrillation February 26, 2008:828–35ndependently associated with an increased risk for the
evelopment or recurrence of AF (18). The capacity of
tatins to reduce inflammation and CRP levels is relatively
ell established (19,20). This might explain a potential
eneficial effect of statins against AF. However, we were not
ble to establish a clear relation between the decrease in
RP with statin use and the benefit obtained against AF.
aseline Biochemical Characteristics of the Patients in theTrials Included in the Meta-Analysis and Changes With Statin Th
Table 3 Baseline Biochemical Characteristics of the Patients i6 Trials Included in the Meta-Analysis and Changes W
Study, Year (Ref. #) n
Total Cholesterol
(mg/dl)
LDL Cholesterol
(mg/dl)
Tveit et al., 2004 (3) 114 216 139
MIRACL, 2004 (4) 3,086 207 124
Chello et al., 2006 (5) 40 235 155
Ozaydin et al., 2006 (6) 48 171 99
ARMYDA-3, 2006 (7) 200 — —
Dernellis and Panaretou,
2006 (8)
130 224 154
Compared with the control group.
CRP  C-reactive protein; HDL  high-density lipoprotein; LDL  low-density lipoprotein; other
Figure 3 Effect of Statins on the Occurrence of AF
Effect of statins versus placebo or control regimen on the occurrence of all types
vention of AF (new-onset or post-operative AF, middle panel), or prevention of recu
of patients in the MIRACL study without or with a previous AF, respectively. CI  cSeveral risk factors for atherogenesis, such as age, obesity,
nd hypertension have been associated with increased risk
or the development of AF (1), suggesting an association
etween AF and atherosclerotic vascular disease. Statins are
nown to improve lipid abnormalities. Whether statins have
protective role against AF development through anti-
therogenic properties remains to be established.
atin Therapy
holesterol
g/dl)
Triglycerides
(mg/dl)
CRP
(mg/dl)
Decrease in LDL
With Statin
Change in CRP
With Statin*
— — — 33% —
46 184 11.25 55% 34%
48 157 — — —
44 140 2.85 9% 10%
— — 3.65 — 1%
48 110 6.1 37% 50%
ations as in Table 1.
l fibrillation (AF) (i.e., first episode or recurrence of AF, top panel), primary pre-
of AF (lower panel). MIRACL 1 and 2 indicate the effect of statin in subgroups
nce interval; OR  odds ratio.erapy
n the
ith St
HDL C
(mof atria
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February 26, 2008:828–35 Statins and Atrial FibrillationThere is evidence suggesting an association between AF
nd enhanced renin angiotensin system activity. Angioten-
in II has a growth-enhancing effect on cardiac myocytes,
ascular smooth muscle cells, and fibroblasts, thus resulting
n remodeling and fibrosis of the atria that could also
rovide a potential arrhythmogenic substrate for the devel-
pment of AF (21). This association is supported by the fact
hat inhibition of the renin angiotensin system might
ecrease the incidence of AF (22). There is also evidence
uggesting an interaction between dyslipidemia and renin
ngiotensin system activity (23). Statins decrease both
holesterol levels and oxidative stress (24) and thus might
ownregulate the renin angiotensin system. This mecha-
Figure 4 Effect of Atorvastatin on the Occurrence of AF
Effect of atorvastatin versus placebo or control regimen on the occurrence of
first AF episode (new-onset or post-operative AF) or recurrence of AF. Abbreviations
Figure 5 Effect of Statins on the Occurrence of AF in Studies P
Effect of statins versus placebo or control regimen on the occurrence of first AF ep
AF in studies published in full text form is on the top panel and OR in studies with
lower methodological quality were excluded from the analysis. Abbreviations as inism might explain a possible antiarrhythmic effect of
tatins against AF (23).
Finally, it has been suggested that a modulation of the
utonomic nervous system by statins might have a protective
ole against AF in the particular setting of postoperative
atients with enhanced sympathetic activity (25).
Meta-analyses might help the integration of current
vidence into clinical practice. There is a need for contin-
ally updating meta-analyses when new randomized con-
rolled trials are available and to perform meta-analysis with
sufficient power from all published trials. Findings from
eta-analyses change when data from a trial with a sub-
tantial number of patients are added, especially when
Figure 3.
hed in Full Text Form and in Studies With Jadad Score >3
(new-onset or postoperative AF) or recurrence of AF. Odds ratio for occurrence of
score 3 is on the lower panel. Jadad score 3 indicates that studies with a
3.as inublis
isode
Jadad
Figure
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Statins and Atrial Fibrillation February 26, 2008:828–35revious ORs border on the threshold of statistical signifi-
ance (26,27). An additional trial comparing 10 mg of
osuvastatin with placebo in heart failure of ischemic etiol-
gy, CORONA (Controlled Rosuvastatin Multinational
tudy in Heart Failure) (28), is ongoing. Atrial fibrillation is
 common event in these patients. This trial combined with
ur meta-analysis should provide further information, if
esults on the end point of incidence of AF become
vailable. Results about statins and AF from new random-
zed studies will then be difficult to obtain in the particular
opulation of patients with coronary artery disease, because
t will seem unethical to build a study including a control
rm without any statin in these patients. Patients with
oronary heart disease are currently treated with statins in
ost cases, and this might not have an impact on their
reatment. In contrast but possibly very interestingly, it
emains to be determined whether statins might bring some
enefit in patients with AF without any type of established
therosclerotic disease or with a low risk of atherogenesis.
tudy limitations. The Jadad score was low in some
tudies, and it is noteworthy that the results of the MIR-
CL study with AF have not been published in a full text
rticle to date. However, results were similar when the
IRACL study was not included in our analysis or when
Rs were calculated after studies with Jadad score 3 were
emoved.
We were not able to assess the degree of low-density
ipoprotein cholesterol (LDL)-lowering versus the inci-
ence or recurrence of AF, as was done with other events
ith statin therapy (29). We cannot determine from our
nalysis whether the benefit was seen because some type or
ose of statins was used or because low LDL levels were
chieved. Thus, if a patient achieved a certain goal of LDL
100 or 70 mg/dl) with moderate-dose statin, we are not
ble to say whether outcomes would be better if a higher-
ose statin was used.
Finally, mechanisms of AF might be varied in different
roups of patients. The benefit of intervention therapies
ight be due to different protective effects, and results
annot be directly extrapolated to specific clinical settings.
ignificant heterogeneity found in OR calculations might
lso reflect heterogeneity of different clinical settings in-
luded in the study.
onclusions
se of statins was significantly associated with a decreased
isk of incidence or recurrence of AF in patients in sinus
hythm with a history of previous AF, in those undergoing
ardiac surgery, or after acute coronary syndrome. These
esults provide some evidence of the benefit of statins
eyond their lipid-lowering activity. However, large-scale,
rospective, randomized clinical trials are still needed to
stablish whether statins bring a similar benefit and are an
ppropriate therapeutic option in all subgroups of patients
or the management of AF.
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